Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2014  |  Volume : 27  |  Issue : 2  |  Page : 497-502

Plasma urotensin II as a marker for severity of rheumatic mitral regurgitation


1 Department of Biochemistry, Faculty of Medicine, Menoufiya University, Menoufiya, Egypt
2 Department of Cardiology, Faculty of Medicine, Menoufiya University, Menoufiya, Egypt
3 Department of Cardiology, Nasser Institute Hospital, Egypt

Correspondence Address:
Ibrahim Elmadbouh
MD, PhD, Biochemistry Department, Faculty of Medicine, Menoufiya University, Yassin Abdel-Ghaffar St, Shebin El-Kom, Menoufiya
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1110-2098.141736

Rights and Permissions

Objectives The aim of the present study was to measure plasma urotensin II concentrations in patients with rheumatic mitral regurgitation, and to examine its correlation with severity of valve impairment, function [New York Heart Association (NYHA)] class, and pulmonary artery pressure (PAP). Background Urotensin II is mainly regarded as a cardiovascular autacoid/hormone; it is associated with different cardiovascular diseases. It might have a pathophysiological role in heart valve disease. Patients and methods A total of 35 patients with moderate-to-severe rheumatic mitral valve regurgitation and 20 healthy controls were selected after performing the echocardiography. Plasma urotensin II level was measured for all participants. Results Urotensin II level was highly significant in patients with mitral valve regurgitation (1.83 ± 0.92 ng/ml) versus the controls (0.48 ± 0.13 ng/ml, P < 0.001). In addition, there was a significant positive correlation between urotensin II level and left ventricular end-diastolic diameter (LVEDD) (r = 0.318, P = 0.03) and PAP (r = 0.706, P < 0.001), but there was no significant correlation between urotensin II level and left ventricular end-systolic diameter (r = 0.271, P = 0.115). Linear regression analysis of LVEDD (r2 linear = 0.101, P < 0.05) and PAP (r2 linear = 0.498, P < 0.001), two among the multiple echocardiographic parameters that predict elevated urotensin II level, was carried out. Conclusion Urotensin II was found to be elevated in patients with rheumatic mitral regurgitation, and positively correlated with increased LVEDD and PAP. Elevation of LVEDD and PAP was found to have a strong prediction for the elevated level of urotensin II. Therefore, urotensin II level may be used as a diagnostic and prognostic marker for severity in patients with rheumatic mitral valvular diseases.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed619    
    Printed9    
    Emailed0    
    PDF Downloaded62    
    Comments [Add]    

Recommend this journal